Medizin
Refine
Year of publication
Document Type
- Article (3562)
- Doctoral Thesis (1082)
- Part of Periodical (199)
- Conference Proceeding (85)
- Book (69)
- Contribution to a Periodical (60)
- Working Paper (21)
- Review (18)
- Preprint (15)
- Part of a Book (10)
Language
Keywords
- inflammation (51)
- apoptosis (30)
- glioblastoma (29)
- breast cancer (26)
- cancer (26)
- Inflammation (21)
- biomarker (18)
- Apoptosis (17)
- COVID-19 (17)
- Depression (17)
Institute
- Medizin (5137) (remove)
Plus Puls : 2016, 3
(2016)
Plus Puls : 2016, 2
(2016)
BACKGROUND: Human SAMHD1 is a triphosphohydrolase that restricts the replication of retroviruses, retroelements and DNA viruses in noncycling cells. While modes of action have been extensively described for human SAMHD1, only little is known about the regulation of SAMHD1 in the mouse. Here, we characterize the antiviral activity of murine SAMHD1 with the help of knockout mice to shed light on the regulation and the mechanism of the SAMHD1 restriction and to validate the SAMHD1 knockout mouse model for the use in future infectivity studies.
RESULTS: We found that endogenous mouse SAMHD1 restricts not only HIV-1 but also MLV reporter virus infection at the level of reverse transcription in primary myeloid cells. Similar to the human protein, the antiviral activity of murine SAMHD1 is regulated through phosphorylation at threonine 603 and is limited to nondividing cells. Comparing the susceptibility to infection with intracellular dNTP levels and SAMHD1 phosphorylation in different cell types shows that both functions are important determinants of the antiviral activity of murine SAMHD1. In contrast, we found the proposed RNase activity of SAMHD1 to be less important and could not detect any effect of mouse or human SAMHD1 on the level of incoming viral RNA.
CONCLUSION: Our findings show that SAMHD1 in the mouse blocks retroviral infection at the level of reverse transcription and is regulated through cell cycle-dependent phosphorylation. We show that the antiviral restriction mediated by murine SAMHD1 is mechanistically similar to what is known for the human protein, making the SAMHD1 knockout mouse model a valuable tool to characterize the influence of SAMHD1 on the replication of different viruses in vivo.
Gallbladder cancer (GBC) is a highly malignant tumor characterized by a poor response to chemotherapy and radiotherapy. We evaluated the in vitro and in vivo antitumor efficacy of mTOR inhibitors, rapamycin and WYE-354. In vitro assays showed WYE-354 significantly reduced cell viability, migration and invasion and phospho-P70S6K expression in GBC cells. Mice harboring subcutaneous gallbladder tumors, treated with WYE-354 or rapamycin, exhibited a significant reduction in tumor mass. A short-term treatment with a higher dose of WYE-354 decreased the tumor size by 68.6% and 52.4%, in mice harboring G-415 or TGBC-2TKB tumors, respectively, compared to the control group. By contrast, treatment with a prolonged-low-dose regime of rapamycin almost abrogated tumor growth, exhibiting 92.7% and 97.1% reduction in tumor size, respectively, compared to control mice. These results were accompanied by a greater decrease in the phosphorylation status of P70S6K and a lower cell proliferation Ki67 index, compared to WYE-354 treated mice, suggesting a more effective mTOR pathway inhibition. These findings provide a proof of concept for the use of rapamycin or WYE-354 as potentially good candidates to be studied in clinical trials in GBC patients.
BACKGROUND: Toxoplasmosis endangers the unborn child if its infectious agent--toxoplasma gondii--is transmitted transplacentally during pregnancy. Although this condition occurs in all parts of the world and represents a major public health burden, no detailed knowledge on the global research architecture of congenital toxoplasmosis is available thus far. Hence, it was the aim of this study to assess the related global research activity over the past 110 years.
METHODS: We employed the NewQIS platform, which combines established scientometric and socioeconomic analysis tools with novel visualizing techniques such as density equalizing mapping projections.
RESULTS: In the Web of Science, 13,044 congenital toxoplasmosis-related items published between 1900 and 2012 were identified. These were issued by 26,483 authors originating from 125 countries. The US was the dominating nation (38.7 % of total scientific output), followed by France (10.9 %) and Great Britain (9.2 %). The US also led the ranking in regards to semi-qualitative parameters (total citations, country-specific h-indices and citation rates). When research activity was related to economic figures, the ratio of total toxoplasmosis publications to the total GDP listed Switzerland first with an average of 589.35 toxoplasmosis-related publications per GDP in 1000 Bio US-$, followed by France (545.16), the UK (486.13) and Brazil (431.84) and the US (311.11). The relation of toxoplasmosis-specific publications to the economic power indicator GDP per capita in 1000 US-$ revealed that the US was ranked first with 97.65 toxoplasmosis-related publications/GDP per capita in 1000 US-$, followed by Brazil (85.95). Subject area analysis indicated a relative shortage of studies that addressed pharmacological or public health aspects of congenital toxoplasmosis.
CONCLUSIONS: This study is the first in-depth approach to sketch a global picture of the congenital toxoplasmosis research architecture. In contrast to other fields of biomedical research, not only high-income countries play a major role regarding congenital toxoplasmosis research but also countries such as Brazil that have a high incidence of congenital toxoplasmosis.
kurz und kn@pp news : Nr. 37
(2016)
Die Relevanz von MSC aus Fettgewebe (ASC) in der regenerativen Medizin überrascht in Anbetracht ihrer breit gefächerten Eigenschaften nicht. Neben antiinflammatorischen Eigenschaften und Hypoxieresistenz können sie in eine Vielzahl von Geweben differenzieren und in geschädigtes Gewebe migrieren, wo sie an Reperaturvorgängen beteiligt sind. Dabei stehen unterschiedliche Quellen zur Isolierung von MSC (und ASC) zur Verfügung. Um ASC therapeutisch einsetzen zu können, ist es essentiell ihre Quellen und ihr Potenzial zu erforschen. Es konnte gezeigt werden, dass perirenales Fettgewebe eine geeignete Quelle für ASC (prASC) darstellt. Der Nachweis der Oberflächenantigene CD73, CD90 und CD105 mittels Durchflusszytometrie sowie die Fähigkeit der prASC an Zellkulturplastik zu adhärieren, erlauben die Schlussfolgerung, dass es sich bei den nach einem bereits etablierten Verfahren isolierten Zellen um MSC handelt. Außerdem konnte durch eine zweiwöchige Kultivierung der prASC in supplementierten Medien die Differenzierung in Adipozyten, Chondrozyten sowie Osteozyten induziert werden. Der Nachweis erfolgte durch cytochemische Färbemethoden. In dieser Arbeit wurde die Differenzierung von prASC in Epithelzellen untersucht. Dafür wurden die Zellen in unterschiedlichen ATRA-haltigen Kulturmedien und konditioniertem Medium aus Tubulusepithelzellen kultiviert. Der Einfluss der Medien wurde mittels Western Blot, qPCR und Immunfluoreszenzfärbung nachgewiesen. Die Kultivierung mit ATRA führte zu einer signifikanten Erhöhung der Expression von CK18 und ZO-1. Dabei handelt es sich um Marker, die charakteristisch für Epithelzellen sind. Es konnte folglich gezeigt werden, dass humane prASC in vitro eindeutig in epithelialer Richtung differenzieren können. Unter dem Einfluss von ATRA-supplementierten Medien exprimierten die kultivierten Zellen Genprodukte, die Epithelzellen zuzuordnen sind.
Welche Bedeutung diese Erkenntnis hat ist noch unklar. Möglicherweise sind prASC, als Stammzellen aus Nischen mit anatomischer Nähe zu den Nieren, potente Kandidaten, um untergegangenes Nierengewebe, wie beispielsweise Tubulusepithelzellen, zu ersetzen.
In der vorliegenden Arbeit wurde das Auftreten einer Fatigue und Depression mit verschiedenen Messinstrumenten in den beiden Vergleichsgruppen Patienten mit einem Prostatakarzinom unter GnRH-Analoga-Therapie im Vergleich zu Patienten mit einem benignen Prostatasyndrom (BPS) untersucht.
Dabei wurde neben der Erhebung des sozioökonomischen Status eine Befragung mittels Brief Fatigue Inventory (BFI), EORTC-QLQ-C30 und dem Beck Depressions-Inventar (BDI) durchgeführt. Die Hypothese war, dass kein Unterschied im Vorhandensein der beiden Merkmale Fatigue und Depression zwischen den beiden Gruppen besteht.
Insgesamt konnten 102 Prostatakarzinom- und 100 BPS-Patienten in die zuvor von der Ethikkommission der Landesärztekammer Hessen genehmigte Studie eingeschlossen werden. Die Datenerhebung erfolgte an ambulanten Patienten in den urologischen Praxisstandorten Prof. Dr. Bickeböller (Frankfurt) und PD Dr. Engl (Oberursel).
In der Auswertung stellte sich ein signifikanter Unterschied hinsichtlich des Durchschnittsalters der Probanden (74,2 Jahre bei den Prostatakarzinompatienten, 70,1 Jahre bei den BPS-Patienten) dar. Bei der Schulbildung und dem Familienstand bestand kein signifikanter Unterschied.
Es konnte gezeigt werden, dass die Fatigue gemessen mittels BFI-Score keinen signifikanten Unterschied zwischen den beiden Gruppen erreichte. Der mittlere BFI-Score bei den Prostatakarzinompatienten lag bei 2,86 und bei den BPS-Patienten bei 2,79 Punkten. Von einer behandlungsbedüftigen, klinisch relevanten Fatigue spricht man nach allgemeinem Konsens bei einem Punktewert > 3. Diese lag bei 36,7% der Prostatakarzinompatienten und bei 33,7% der BPS-Patienten vor (p = 0,321).
Im EORTC-QLQ C30 Fragebogen ergaben sich signifikante Unterschiede für die Funktionscores Rollenfunktion (p = 0,038) und physische Funktion (p = 0,020) sowie für den Symptomscore Fatigue (FA-Score) (p = 0,047) zugunsten der BPS-Patienten, die jeweils bessere Werte erzielten. Dabei lag der durchschnittliche Punktewert der Rollenfunktion bei den Prostatakarzinompatienten mit 70,1 Punkten niedriger als bei den BPS-Patienten mit 77,5 Punkten. Der durchschnittliche Score für die physische Funktion lag bei den Prostatakarzinompatienten bei 71,0 Punkten (BPS-Patienten 78,4 Punkte) und der FA-Score bei 38,3 Punkten (BPS-Patienten 31,4 Punkte), wobei berücksichtigt werden muss, dass beim FA-Score niedrigere Punktewerte ein geringeres Ausmaß an Fatigue repräsentieren.
Der BDI offenbarte signifikante Unterschiede (Angabe in Mittelwerten) bei den Attributen „Selbstkritik“ (Prostatakarzinompatienten 0,23 Punkte, BPS-Patienten 0,44 Punkte, p = 0,015), „Energieverlust“ (Prostatakarzinompatienten 1,01 Punkte, BPS-Patienten 0,71 Punkte, p = 0,020) und „Verlust an sexuellem Interesse“ (Prostatakarzinompatienten 1,65 Punkte, BPS-Patienten 0,69 Punkte, p = 0,000). Von einer milden depressiven Symptomatik spricht man vereinbarungsgemäß ab einem BDI-Gesamt-Mittelwert von ≥ 14 Punkten. Der Mittelwert unserer beiden Vergleichsgruppen lag bei 10,29 (Prostatakarzinompatienten) und 8,6 (Patienten mit BPS) und war mit p = 0,608 nicht signifikant unterschiedlich. Eine Korrelation zwischen Fatigue und Depression konnte nicht erfolgen, da die Anzahl der Patienten mit einer moderaten/schweren Depression aufgrund der kleinen Fallzahl zu gering war.
Insgesamt konnte bei keinem der untersuchten Messinstrumente eine signifikante Korrelation zum Alter oder zum Familienstand festgestellt werden. Es zeigte sich ein signifikanter Unterschied (p = 0,029) im Vergleich der Schulbildung zum Ausmaß der Fatigue im FA-Score bei Prostatakarzinompatienten zuungunsten einer niedrigeren Schulbildung. Bei den BPS-Patienten konnte dieser Sachverhalt nicht gezeigt werden.
Zusammenfassend kann festgestellt werden, dass kein signifikanter Unterschied der beiden Gruppen in Hinblick auf das Ausmaß der Fatigue gemessen mit dem BFI-Score und das Auftreten einer Depression gemessen mit dem BDI besteht. Der signifikante Unterschied der Fatigue gemessen mittels FA-Score des EORTC-QLQ-C30 Fragebogens kann mit einem von Knobel et al. beschriebenen floor/ceiling effect erklärt werden, der bei Karzinompatienten das Ausmaß der Fatigue aufgrund von physischen Einschränkungen überschätzt und bei gesunden Patienten unterschätzt.
Dass Patienten mit einer benignen Grunderkrankung wie dem Prostatasyndrom im gleichen Ausmaß an Fatigue leiden wie Prostatakarzinompatienten wurde in unserer Arbeit erstmalig gezeigt und bedarf der weiteren Forschung, da die bislang bekannten pathophysiologischen Faktoren der Fatigue kein ausreichendes Erklärungsmodell bieten. Eine gestörte Nachtruhe durch die vermehrt im Rahmen des BPS auftretende Nykturie kann als eine der Ursachen angenommen werden, diesbezüglich sollten zukünftig weitere Untersuchungen stattfinden.
Breast cancer is fast becoming the leading cause of oncologic morbidity and mortality among women worldwide. Demographic changes in Asia, Southeast Asia, and South America will further accelerate this trend. Different specialties are involved in the treatment of breast cancer patients: gynecology, surgery, pathology, hematology/oncology, radiology, radiation oncology, and nuclear medicine. Optimal results are seen in countries providing standardized breast cancer care in certified breast centers. The present article provides an overview of current state-of-the-art treatment strategies and explains the contributions of different specialties to optimal and individualized care for breast cancer patients. Breast cancer will be one of the most important health issues facing physicians involved with women’s health and a basic understanding of current treatment objectives will be essential medical knowledge for everyone taking care of female patients.
Nuclear export factor 1 (NXF1) exports mRNA to the cytoplasm after recruitment to mRNA by specific adaptor proteins. How and why cells use numerous different export adaptors is poorly understood. Here we critically evaluate members of the SR protein family (SRSF1-7) for their potential to act as NXF1 adaptors that couple pre-mRNA processing to mRNA export. Consistent with this proposal, >1000 endogenous mRNAs required individual SR proteins for nuclear export in vivo. To address the mechanism, transcriptome-wide RNA-binding profiles of NXF1 and SRSF1-7 were determined in parallel by individual-nucleotide-resolution UV cross-linking and immunoprecipitation (iCLIP). Quantitative comparisons of RNA-binding sites showed that NXF1 and SR proteins bind mRNA targets at adjacent sites, indicative of cobinding. SRSF3 emerged as the most potent NXF1 adaptor, conferring sequence specificity to RNA binding by NXF1 in last exons. Interestingly, SRSF3 and SRSF7 were shown to bind different sites in last exons and regulate 3' untranslated region length in an opposing manner. Both SRSF3 and SRSF7 promoted NXF1 recruitment to mRNA. Thus, SRSF3 and SRSF7 couple alternative splicing and polyadenylation to NXF1-mediated mRNA export, thereby controlling the cytoplasmic abundance of transcripts with alternative 3' ends.
An increasing body of evidences from preclinical as well as epidemiological and clinical studies suggest a potential beneficial role of dietary intake of omega-3 fatty acids for cognitive functioning. In this narrative review, we will summarize and discuss recent findings from epidemiological, interventional and experimental studies linking dietary consumption of omega-3 fatty acids to cognitive function in healthy adults. Furthermore, affective disorders and schizophrenia (SZ) are characterized by cognitive dysfunction encompassing several domains. Cognitive dysfunction is closely related to impaired functioning and quality of life across these conditions. Therefore, the current review focues on the potential influence of omega-3 fatty acids on cognition in SZ and affective disorders. In sum, current data predominantly from mechanistic models and animal studies suggest that adjunctive omega-3 fatty acid supplementation could lead to improved cognitive functioning in SZ and affective disorders. However, besides its translational promise, evidence for clinical benefits in humans has been mixed. Notwithstanding evidences indicate that adjunctive omega-3 fatty acids may have benefit for affective symptoms in both unipolar and bipolar depression, to date no randomized controlled trial had evaluated omega-3 as cognitive enhancer for mood disorders, while a single published controlled trial suggested no therapeutic benefit for cognitive improvement in SZ. Considering the pleiotropic mechanisms of action of omega-3 fatty acids, the design of well-designed controlled trials of omega-3 supplementation as a novel, domain-specific, target for cognitive impairment in SZ and affective disorders is warranted.
The current Review article provides a narrative review about the neurobiological underpinnings and treatment of treatment resistant late-life depression (TRLLD). The manuscript focuses on therapeutic targets of late-life depression, which include pharmacological, psychological, biophysical and exercise treatment approaches. Therefore, we summarize available evidences on that kind of therapies for patients suffering from late-life depression. The search for evidences of therapeutic options of late-life depression were done using searching websites as “pubmed”, and using the searching terms “depression”, “late-life depression”, “treatment”, “biophysical therapy”, “exercise therapy”, “pharmacological therapy” and “psychological therapy”. To the end, we summarize and discuss current data, providing some directions for further research.
Treatment recommendations for elderly depressive patients favour a multimodal approach, containing psychological, pharmacological and secondary biophysical therapeutic options. Particularly, a combination of psychotherapy and antidepressant medication reflects the best therapeutic option. However, mostly accepted and used is the pharmacological treatment although evidence suggests that the drug therapy is not as effective as it is in younger depressive patients. Further studies employing larger samples and longer follow-up periods are necessary and may focus on comparability of study designs and involve novel approaches to establish the validity and reliability of multimodal treatment programs.
Understanding how to achieve efficient transduction of hematopoietic stem and progenitor cells (HSPCs), while preserving their long-term ability to self-reproduce, is key for applying lentiviral-based gene engineering methods. SAMHD1 is an HIV-1 restriction factor in myeloid and resting CD4+ T cells that interferes with reverse transcription by decreasing the nucleotide pools or by its RNase activity. Here we show that SAMHD1 is expressed at high levels in HSPCs cultured in a medium enriched with cytokines. Thus, we hypothesized that degrading SAMHD1 in HSPCs would result in more efficient lentiviral transduction rates. We used viral like particles (VLPs) containing Vpx, shRNA against SAMHD1, or provided an excess of dNTPs or dNs to study this question. Regardless of the method applied, we saw no increase in the lentiviral transduction rate. The result was different when we used viruses (HR-GFP-Vpx+) which carry Vpx and encode GFP. These viruses allow assessment of the effects of Vpx specifically in the transduced cells. Using HR-GFP-Vpx+ viruses, we observed a modest but significant increase in the transduction efficiency. These data suggest that SAMHD1 has some limited efficacy in blocking reverse transcription but the major barrier for efficient lentiviral transduction occurs before reverse transcription.
Despite multimodal regimens and diverse treatment options alleviating disease symptoms, morbidity and mortality associated with advanced ischemic heart failure remain high. Recently, technological innovation has led to the development of regenerative therapeutic interventions aimed at halting or reversing the vicious cycle of heart failure progression. Driven by the unmet patient need and fueled by encouraging experimental studies, stem cell-based clinical trials have been launched over the past decade. Collectively, these trials have enrolled several thousand patients and demonstrated the clinical feasibility and safety of cell-based interventions. However, the totality of evidence supporting their efficacy in ischemic heart failure remains limited. Experience from the early randomized stem cell clinical trials underscores the key points in trial design ranging from adequate hypothesis formulation to selection of the optimal patient population, cell type and delivery route. Importantly, to translate the unprecedented promise of regenerative biotherapies into clinical benefit, it is crucial to ensure the appropriate choice of endpoints along the regulatory path. Accordingly, we here provide considerations relevant to the choice of endpoints for regenerative clinical trials in the ischemic heart failure setting.
As current classical Hodgkin lymphoma (cHL) treatment strategies have pronounced side-effects, specific inhibition of signaling pathways may offer novel strategies in cHL therapy. Basal autophagy, a regulated catabolic pathway to degrade cell's own components, is in cancer linked with both, tumor suppression or promotion. The finding that basal autophagy enhances tumor cell survival would thus lead to immediately testable strategies for novel therapies. Thus, we studied its contribution in cHL.We found constitutive activation of autophagy in cHL cell lines and primary tissue. The expression of key autophagy-relevant proteins (e.g. Beclin-1, ULK1) and LC3 processing was increased in cHL cells, even in lymphoma cases. Consistently, cHL cells exhibited elevated numbers of autophagic vacuoles and intact autophagic flux. Autophagy inhibition with chloroquine or inactivation of ATG5 induced apoptosis and reduced proliferation of cHL cells. Chloroquine-mediated inhibition of basal autophagy significantly impaired HL growth in-vivo in NOD SCID γc-/- (NSG) mice. We found that basal autophagy plays a pivotal role in sustaining mitochondrial function.We conclude that cHL cells require basal autophagy for growth, survival and sustained metabolism making them sensitive to autophagy inhibition. This suggests basal autophagy as useful target for new strategies in cHL treatment.
The aim of this preliminary prospective RCT was to histologically evaluate peri-implant soft tissues around titanium abutments treated using different cleaning methods. Sixteen patients were randomized into three groups: laboratory customized abutments underwent Plasma of Argon treatment (Plasma Group), laboratory customized abutments underwent cleaning by steam (Steam Group), and abutments were used as they came from industry (Control Group). Seven days after the second surgery, soft tissues around abutments were harvested. Samples were histologically analyzed. Soft tissues surrounding Plasma Group abutments predominantly showed diffuse chronic infiltrate, almost no acute infiltrate, with presence of few polymorphonuclear neutrophil granulocytes, and a diffuse presence of collagenization bands. Similarly, in Steam Group, the histological analysis showed a high variability of inflammatory expression factors. Tissues harvested from Control Group showed presence of few neutrophil granulocytes, moderate presence of lymphocytes, and diffuse collagenization bands in some sections, while they showed absence of acute infiltrate in 40% of sections. However, no statistical difference was found among the tested groups for each parameter (p > 0.05). Within the limit of the present study, results showed no statistically significant difference concerning inflammation and healing tendency between test and control groups.
OBJECTIVES: Outcome of aortic valve replacement may be influenced by the choice of bioprosthesis. Pericardial heart valves are described to have a favourable haemodynamic profile compared with porcine valves, although the clinical notability of this finding is still controversially debated. Herein, we compared the long-term results of two commonly implanted bioprosthesis at a single centre.
METHODS: All consecutive patients undergoing isolated aortic valve replacement with either a Carpentier-Edwards Magna pericardial prosthesis or a Medtronic Mosaic porcine prosthesis between 2002 and 2008 were analysed regarding preoperative characteristics, short- and long-term survival, valve-related complications and echocardiographic findings.
RESULTS: The Medtronic Mosaic was implanted in 163 patients and the Carpentier-Edwards Magna in 295 patients. The sizes of implanted valves were 22.4 ± 1.5 mm for the Mosaic and 21.8 ± 1.8 mm for the Magna (P = 0.001). The long-term survival rate was 76 and 56% after 5 and 10 years for the Medtronic Mosaic, which was comparable with the Carpentier-Edwards Magna (77 and 57%; P = 0.92). Overall long-term survival was comparable with an age- and sex-matched Austrian general population for both groups. Valve-related adverse events were similar between groups. The postoperative mean transvalvular gradient was significantly increased in the Mosaic group (24 ± 9 mmHg vs 17 ± 7 mmHg; P < 0.001).
CONCLUSIONS: Both types of aortic bioprostheses offer excellent results after isolated aortic valve replacement. Despite relevant differences in gradients, long-term survival was comparable with the expected normal survival for both bioprostheses. Patients with a porcine heart valve had a higher postoperative transvalvular gradient.
The processing of pain undergoes several changes in aging that affect sensory nociceptive fibers and the endogenous neuronal inhibitory systems. So far, it is not completely clear whether age-induced modifications are associated with an increase or decrease in pain perception. In this study, we assessed the impact of age on inflammatory nociception in mice and the role of the hormonal inhibitory systems in this context. We investigated the nociceptive behavior of 12-month-old versus 6–8-week-old mice in two behavioral models of inflammatory nociception. Levels of TRP channels, and cortisol as well as cortisol targets, were measured by qPCR, ELISA, and Western blot in the differently aged mice. We observed an age-related reduction in nociceptive behavior during inflammation as well as a higher level of cortisol in the spinal cord of aged mice compared to young mice, while TRP channels were not reduced. Among potential cortisol targets, the NF-κB inhibitor protein alpha (IκBα) was increased, which might contribute to inhibition of NF-κB and a decreased expression and activity of the inducible nitric oxide synthase (iNOS). In conclusion, our results reveal a reduced nociceptive response in aged mice, which might be at least partially mediated by an augmented inflammation-induced increase in the hormonal inhibitory system involving cortisol.
Objectives: Patient safety is a crucial issue in medicine. Its main objective is to reduce the number of deaths and health damages that are caused by preventable medical errors. To achieve this, it needs better health systems that make mistakes less likely and their effects less detrimental without blaming health workers for failures. Until now, there is no in-depth scientometric analysis on this issue that encompasses the interval between 1963 and 2014. Therefore, the aim of this study is to sketch a landscape of the past global research output on patient safety including the gender distribution of the medical discipline of patient safety by interpreting scientometric parameters. Additionally, respective future trends are to be outlined.
Setting: The Core Collection of the scientific database Web of Science was searched for publications with the search term ‘Patient Safety’ as title word that was focused on the corresponding medical discipline. The resulting data set was analysed by using the methodology implemented by the platform NewQIS. To visualise the geographical landscape, state-of-the-art techniques including density-equalising map projections were applied.
Results: 4079 articles on patient safety were identified in the period from 1900 to 2014. Most articles were published in North America, the UK and Australia. In regard to the overall number of publications, the USA is the leading country, while the output ratio to the population of Switzerland was found to exhibit the best performance. With regard to the ratio of the number of publications to the Gross Domestic Product (GDP) per Capita, the USA remains the leading nation but countries like India and China with a low GDP and high population numbers are also profiting.
Conclusions: Though the topic is a global matter, the scientific output on patient safety is centred mainly in industrialised countries.